QFA
DRUG

Quattro Financial Advisors’s Bright Minds Biosciences DRUG Stock Holding History

Quattro Financial Advisors’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,230
Closed -$9.31K – 87
2023
Q1 		$9.31K Hold
4,230
– – ﹤0.01% 83
2022
Q4 		$15.7K Hold
4,230
– – 0.01% 78
2022
Q3 		$26K Hold
4,230
– – 0.01% 85
2022
Q2 		$17K Hold
4,230
– – 0.01% 85
2022
Q1 		$32K Hold
4,230
– – 0.01% 81
2021
Q4 		$67K Buy
+4,230
New +$94.1K 0.02% 98

Other funds holding DRUG

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Quattro Financial Advisors's DRUG Position: Q2 2023 in Review

Quattro Financial Advisors sold out of Bright Minds Biosciences (DRUG) in Q2 2023, closing a stake of 4,230 shares — an estimated $9.31K sold.

Quattro Financial Advisors first reported a position in DRUG in Q4 2021 and held it in 6 quarters. The position peaked at $67K in Q4 2021. 8 funds tracked by Wall St. Rank hold DRUG as of Q2 2023.

  • Quattro Financial Advisors reported no remaining Bright Minds Biosciences position as of Q2 2023 after selling out during the quarter.
  • Quattro Financial Advisors sold 4,230 Bright Minds Biosciences shares in Q2 2023, an estimated $9.31K.
  • Quattro Financial Advisors first reported a position in Bright Minds Biosciences in Q4 2021 and held it in 6 quarters.
  • Quattro Financial Advisors's Bright Minds Biosciences position peaked at $67K in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2023.

Based on Quattro Financial Advisors's 13F filing for Q2 2023, filed 25 Jul 2023.